Notes from May 2023 concall:
- Albumin - Phase-1 started, expected to launch by the end of 2024. No chances of product rejection in phase trials. This product has a 9 billion$ market. It’s an all-over-the-world shortage product.
- Aflibercept - a complex product in the ophthalmic range. Starting phase-3 trials in India. Trying to develop this particular product for the global market.
- Adalimumab - launching in India this quarter, targeting 25 cr. Annual sales
- As per management double-digit growth is definitely possible for the API and the onco, non-onco, polymer, peptide, and CDMO business, each of the divisions will grow this year.
- They have invested 600cr. for Dharwad facility till now.
- Only 75 cr. Capex planned for the coming FY for the product albumin
- All the remediation measures are almost completed. FDA has seen their compliance reports. The date is still unknown for their visit.
- Trying their best to deleverage with all the possible options.
Technically, the stock is trying to form a base around 225. For now, it has stopped making new lows. A breakout from this rectangle might make a case for a turnaround.
